

Publikationsliste Dr. Boris-A. Kallmann

- 1 **B.A.Kallmann**, V.Burkart, K.-D.Kröncke, V.Kolb-Bachofen, H. Kolb
Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide.
Life Sciences 1992 ; 51: 671 – 678
- 2 V.Burkart, Y.Imai, **B.A.Kallmann**, H.Kolb
Cyclosporin A protects pancreatic islet cells from nitric oxide-dependent macrophage cytotoxicity.
FEBS Lett. 1992 ; 313: 56-58
- 3 V.Burkart, A.Jalowy, B.Hartmann, **B.A.Kallmann**, K.Fehsel, H.Kolb
Nitric oxide as a mediator of autoimmunity in insulin-dependent diabetes.
Immunobiology 1992; 186 : 19 - 20
- 4 **B.A.Kallmann**, H.Kolb, M.Hüther, S. Martin, M.Hellermann, E.F.Lampeter
Interleukin-10 is a predominant cytokine in atopic dermatitis.
Archives of Dermatology 1996; 132: 1133-1134
- 5 **B.A.Kallmann**, M.Hüther, M.Tubes, J.Feldkamp, J.Bertrams, F.A.Gries, E.F.Lampeter, H.Kolb
Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease
Diabetes 1997; 46: 237-243
- 6 P.Rieckmann, B.Altenhofen, A.Riegel, **B.A.Kallmann**, K.Felgenhauer
Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis
Multiple Sclerosis 1998; 4: 178-182
- 7 **B.A.Kallmann**, E.F.Lampeter, P.Hanifi-Moghaddam, M.Hawa, R.D.G.Leslie, H.Kolb
Cytokine secretion patterns in twins discordant for type I diabetes
Diabetologia 1999; 42: 1080-1085
- 8 **B.A.Kallmann**, R.Malz Korn, H.Kolb
Exogenous nitric oxide modulates cytokine production in human leucocytes
Life Sciences 1999; 65: 1787-1794
- 9 P.Rieckmann, **B.A.Kallmann**:
Immunological parameters and magnetic resonance imaging activity
Frontiers in Multiple Sclerosis 1999; 2, Ed. A.Siva, J.Kesselring, A.J.Thompson, Martin Dunitz Ltd.: 117-125
- 10 P.Rieckmann, S.Jung, A.Chan, **B.A.Kallmann**, S.Martin
Pathogenesis and therapeutic concepts of organ-specific autoimmune diseases
Autoimmunity 1999; 31: 283-288
- 11 **B.A.Kallmann**, V.Hummel, T.Lindenlaub, K.Ruprecht, K.V.Toyka, P.Rieckmann
Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
Brain 2000; 123: 687-697
- 12 V.Hummel, **B.A.Kallmann**, T.Füller, S.Wagner, A.Bayas, J.Tonn, E.Benveniste, K.V.Toyka, P.Rieckmann
The production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules
Journal of Neuropathology and Experimental Neurology 2001; 60: 320-327
- 13 **Multiple-Sklerose-Therapie-Konsensus-Gruppe**
Immunmodulatorische Stufentherapie der Multiplen Sklerose. 1. Ergänzung: Dezember 2000
Nervenarzt 2001; 72: 150-157
- 14 **Multiple-Sklerose-Therapie-Konsensus-Gruppe**
Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, März 2002
Nervenarzt 2002; 73: 556-563

- 15 **B.A.Kallmann**, S.Wagner, V.Hummel, A.Bayas, J.C.Tonn, P.Rieckmann
Characteristic gene expression profile of primary human cerebral endothelial cells
FASEB J Express, February 12, 2002, 10.1096/fj.01-0594fje
- 16 A.Bayas, V.Hummel, **B.A.Kallmann**, C.Karch, K.V.Toyka, P.Rieckmann
Human cerebral endothelial cells are a potential source for bioactive BDNF
Cytokine 2002; 19 (2): 55-58
- 17 P.Flachenecker, T.Kümpfel, **B.A.Kallmann**, M.Gottschalk, O.Grauer, P.Rieckmann, C.Trenkwalder, K.V.Toyka
Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters
Multiple Sclerosis 2002; 8: 523-526
- 18 U. Michel, **B.A.Kallmann**, P. Rieckmann, D. Isbrandt
UM 9(5)h and UM 9(5)p, a human and a porcine non-coding transcript with preferential expression in the cerebellum
RNA 2002; 8: 1538-1547
- 19 **B.A.Kallmann**, P.Rieckmann
Chemokines and MS lesion development
International Journal of Multiple Sclerosis 2002; 9: 100-107
- 20 G.Martino, L.Adorini, P.Rieckmann, J.Hillert, **B.A.Kallmann**, G.Comi, M.Filippi
Inflammation in multiple sclerosis: the good, the bad, and the complex
Lancet Neurology 2002; 1: 499-509
- 21 **B.A.Kallmann**, P.Rieckmann
Was gibt es Neues in der Multiplen Sklerose?
Akt Neurologie 2003; 30: 421-427
- 22 **B.A.Kallmann**, J.Sauer, M.Schließer, M.Warmuth-Metz, P.Flachenecker, G.Becker, P.Rieckmann, M.Mäurer
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS) – A two year follow-up study
J Neurol 2004; 251: 30-34
- 23 **Multiple Sclerosis Therapy Consensus Group**
Escalating immunotherapy of multiple sclerosis. New aspects and practical application
Journal of Neurology 2004; 251: 1329-1339
- 24 P.Rieckmann, **B.A.Kallmann**
Neue Therapieansätze bei Multipler Sklerose
Nervenheilkunde 2005; 4: 294-300
- 25 **B.A.Kallmann**, S. Büttner, K.V. Toyka, K.Reiners, P. Rieckmann
Predictive value of evoked potentials for long term disease course in Multiple Sclerosis.
Multiple Sclerosis 2006; 12: 58-65
- 26 G. Valenza, **B.A.Kallmann**, A. Berend, R. Mlynski, K. Nöckler, O. Kurzai, M. Frosch, M. Abele-Horn
Isolation of Brucella melitensis from a patient with hearing loss
Eur J Clin Microbiol Infect Dis 2006; DOI 10.1007/s10096-006-0084-4
- 27 **Multiple-Sklerose-Therapie-Konsensus-Gruppe**
Immunmodulatorische Stufentherapie der Multiple Sklerose – aktuelle Therapieempfehlungen (September 2006)
Nervenarzt 2006; 77: 1506-1518
- 28 **Multiple Sclerosis Therapy Consensus Group**
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
J Neurol. 2008; 255:1449-1463
- 29 **Arbeitsgruppe Moderne Immuntherapie der MS des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft**
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern

Akt Neurol 2009; DOI 10.1055/s-0029-1220429

30 A. Bayas, G. Japp, U.Fulda, **B.A.Kallmann**
Injektionshilfen in der Basistherapie der Multiplen Sklerose
Nervenheilkunde 2010; 1-2:57-62

31 **Arbeitsgruppe Moderne Immuntherapie der Multiplen Sklerose**
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings
Akt Neurologie 2011; 38: 2 - 11

32 **B.A.Kallmann**
Multiple Sklerose – Ist eine Neuroprotektion mit aktuellen Therapien möglich?
Neurotransmitter 10 / 2011; 34 – 41

33 Novas M, Sweetser MT, Vigiotta V, Dawson KT; Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, **CONFIRM Study Investigators**
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
N Engl J Med. 2012 Sep 20;367(12):1087-97.

34 R.Gold, H.P.Hartung, M.Stangel, H.Wiendl und die **Teilnehmer eines Expertenmeetings**
Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose
Akt Neurol 2012; 39: 342–350

35 M.Stangel, I.K.Penner, **B.A.Kallmann**, C.Lukas, B.C.Kieseier, R.Gold
Multiple Sclerosis Decision Model (MSDM): Entwicklung eines
Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs
bei schubförmiger Multipler Sklerose
Akt Neurol 2013; 40: 486–493

36 Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; **TOWER Trial Group**.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Neurol. 2014;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

37 **B.A.Kallmann**, M.Mäurer, R.Linker, S.Schwab
Bedeutung regionaler Netzwerke bei der Versorgung von MS-Patienten
DNP - Der Neurologe und Psychiater 2014; 15: 64-67

38 M.Stangel, I.K.Penner, **B.A.Kallmann**, C.Lukas, B.C.Kieseier.
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.
Ther Adv Neurol Disord. 2015; 8(1):3-13. doi: 10.1177/1756285614560733.

39 Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Vigiotta V, Dawson KT; **CONFIRM study investigators**.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Neurology. 2015 Feb 13. pii: 10.1212/WNL.000000000001360. [Epub ahead of print]

40 A Bayas, JC Ouallet, **B Kallmann**, R Hupperts, U Fulda, K Marhardt & for the SMART study group
Adherence to, and effectiveness of, sc IFN b-1a administered by RebiSmart in patients with RMS.
Expert Opin. Drug Deliv. 2015; 12(8)

41 **B.A. Kallmann**, M. Mäurer, R. Linker, S.Schwab
Bedeutung regionaler Netzwerke bei der Versorgung von MS-Patienten
DNP – Der Neurologe und Psychiater, 2014:15 (12)

42 R. Linker, **B.A. Kallmann**, C. Kleinschnitz, P. Rieckmann, M. Mäurer, S. Schwab
„Time is brain“ in relapsing remitting multiple sclerosis: Current treatment concepts in immunotherapy
Der Nervenarzt 2015; 86: 1528-1537

- 43 I. Metz, P. Rieckmann, **B.A. Kallmann**, W. Brück
Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple Sclerosis
Acta Neuropathologica Communications (2016) 4:81- DOI 10.1186/s40478-016-0352-1
- 44 S. Schmidt, J. Koehler, C. Winterstein, P. Schickmaier, **B. Kallmann** for the EPIDEM Investigators
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)
Therapeutic Advances in Neurological Disorders 2018 Jan 23;11:1756285617749802. doi: 10.1177/1756285617749802.
- 45 K. Huhn, A. Bayas, S. Doerck, B. Frank, K. Gerbershagen, K. Hellwig, **B. Kallmann**, C. Kleinschnitz, I. Kleiter, D.H. Lee, V. Limmroth, M. Mäurer, S. Meuth, P. Rieckmann, T. Ruck, R. Gold, R. A. Linker
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: A multi-center observational study.
Journal of Neurology, (<https://doi.org/10.1007/s00415-018-8871-2>)
- 46 A. Haghikia, R. Linker, B. Kallmann, E. Schlegel, B. Tackenberg, T. Ziemssen. Dimethylfumarat –
Therapiemanagement in der neurologischen Praxis. *Thieme Praxis Report* 2018; 10 (■): 1–12
- 47 B.A. Kallmann, K. Tiel-Wilck, J.S. Kullmann, U.Engelmann, A. Chan. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. *Ther Adv Neurol Disord* 2019, Vol. 12: 1–14
- 48 S.G. Meuth, A. Bayas, **B. Kallmann**, C. Kleinschnitz, R. Linker, P. Rieckmann, M. Mäurer. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. *Expert Opin Pharmacother.* 2020 Jul 13;1-5. doi:10.1080/14656566.2020.1792885.
- 49 [Multiple Sclerosis Therapy Consensus Group \(MSTCG\): position statement on disease-modifying therapies for multiple sclerosis \(white paper\).](#)
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, **Kallmann B**, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; 'Multiple Sclerosis Therapy Consensus Group' (MSTCG). *Ther Adv Neurol Disord.* 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021.
- 50 [\[Multiple sclerosis treatment consensus group \(MSTCG\): position paper on disease-modifying treatment of multiple sclerosis 2021 \(white paper\)\].](#)
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, **Kallmann B**, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). *Nervenarzt.* 2021 Aug;92(8):773-801. doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23.
- 51 [Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status.](#)
Kallmann BA, Ries S, Kullmann JS, Quint LM, Engelmann U, Chan A. *Ther Adv Neurol Disord.* 2021 May 18;14:17562864211005588. doi: 10.1177/17562864211005588.
- 52 Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
S.G. Meuth, A. Bayas, **B. Kallmann**, R. Linker, P. Rieckmann, M. Wattjes, M. Mäurer, C. Kleinschnitz.
Expert Opin Pharmacother. 2022 Aug 05. <https://doi.org/10.1080/14656566.2022.2106783>